Dr. Iinuma from ARCALIS’s process development department will present a poster at TIDES USA, Oligonucleotide & Peptide Therapeutics.
Dr. Iinuma from ARCALIS’s process development department will present a poster at TIDES USA, Oligonucleotide & Peptide Therapeutics which will be held from May 11th (Mon) to 14th (Thu), 2026, at the Hynes Convention Center, Boston, USA. We cordially invite all conference participants to visit the poster.
【Event details】
Official website: TIDES USA 2026: Oligonucleotide and Peptide Therapeutics
Date: May 11th (Mon) -14th (Thu), 2026
Venue: Hynes Convention Center, Boston
Access: Hynes | Signature Boston
【Poster presentation】
Title: Novel approach for LNP manufacturing and formulation demonstrating consistent bioactivity and organ-selective delivery at ARCALIS
Presenter: Dr. Hiroto Iinuma
【Abstract】
ARCALIS has established robust manufacturing using different LNP mixers and organ-selective delivery with optimized LNP compositions to develop effective mRNA-LNP therapeutics. Since robust manufacturing requires consistent control of physicochemical properties and critical quality attributes (CQAs) to achieve reproducible bioactivity, mRNA-LNPs were produced using different LNP mixers and mixing technologies. ARCALIS demonstrated that mRNA-LNPs with controlled CQAs exhibited equivalent protein expression regardless of the manufacturing methods. To establish organ-selectivity using rational lipid compositions to direct organ-specific protein expression, LNPs formulated with a panel of ionizable lipids with organ-targeting properties resulted in distinct organ-selective mRNA delivery profiles. Collectively, these results demonstrated ARCALIS’s capabilities for robust, scalable mRNA-LNP manufacturing combined with lipid design to enable consistent bioactivity and controlled organ delivery, underscoring the effectiveness of this technology for next-generation mRNA therapeutics.